Deals·October 19, 2026 at 8:18 AM EDT·4 sources
Merck KGaA to Buy Silence Therapeutics for $1.1 Billion
SLN +0.1%
SLN · last 30 trading days+126.6% since the news
News
acquisition, log scale$1.1B
$100M$1B$10B$100B
What happened
- Merck KGaA agreed to acquire Silence Therapeutics Plc for about $1.1 billion in cash.
- The acquisition is intended to strengthen Merck KGaA’s rare-disease business.
Transaction value
about $1.1 billion
Why it matters
The deal expands Merck KGaA’s position in rare diseases and is relevant to healthcare M&A professionals tracking strategic pharmaceutical acquisitions.
Deal terms
acquisition
Merck KGaA → Silence Therapeutics Plc
Value
$1.1B
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- EarlierOct 19Silence Therapeutics plc: Material agreement
- First reported by BloombergOct 19Merck KGaA to Buy Silence Therapeutics for $1.1 Billion
- The Wall Street Journal reportsOct 19Germany’s Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion
- Endpoints News reportsOct 19Merck KGaA to buy Silence Therapeutics and its siRNA pipeline for $1.3B
- BioPharma Dive reportsOct 19Merck KGaA bets on RNAi with $1.3B Silence buyout
Who is involved
acquiringMerck KGaA to Buy Silence Therapeutics for $1.1 BillionSilence Therapeutics PlcSLN · targetMerck KGaAbuyer
CompanyThe deal
Sources (4)
- BloombergOct 19Merck KGaA to Buy Silence Therapeutics for $1.1 Billion
- The Wall Street JournalOct 19Germany’s Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion
- Endpoints NewsOct 19Merck KGaA to buy Silence Therapeutics and its siRNA pipeline for $1.3B
- BioPharma DiveOct 19Merck KGaA bets on RNAi with $1.3B Silence buyout
Related
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.